Health resource use and cost analysis of schizophrenia patients participating in a randomized, multicenter, double-blind, relapse prevention study of paliperidone palmitate 3-month formulation

Benson, C., Chirila, C., Graham, J., Radder, C., Zheng, Q., & Woodruff, K. (2015). Health resource use and cost analysis of schizophrenia patients participating in a randomized, multicenter, double-blind, relapse prevention study of paliperidone palmitate 3-month formulation. Value in Health, 18(3), A119. https://doi.org/10.1016/j.jval.2015.03.699

Abstract

Clinical trial PSY-3012 was a randomized, multicenter, double-blind, parallel-group, relapse-prevention study of paliperidone palmitate 3-month injection (PP3M) versus placebo. Adults with schizophrenia received a once-monthly injection (PP1M) in an open-label (OL) 17-week transition phase, then a single PP3M injection for OL 12-week maintenance. Stabilized subjects were then randomized to PP3M or placebo in the double-blind (DB) phase. Exploratory objectives were to compare health resource utilization (HRU) and costs between PP3M and placebo.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Long-term effects of a diet supplement containing Cannabis sativa oil and Boswellia serrata in dogs with osteoarthritis following physiotherapy treatments
Article

Community overdose surveillance
Article

Tailoring off the shelf global evidence with local implementation research can boost action on overweight and obesity